The recommended dose of Ivosidenib(Tibsovo) for adults is 500 mg once daily until disease progression or unacceptable toxicity. Patients should take it orally on an empty stomach or after a meal, and avoid eating high-fat meals. The medication should be taken at a fixed time, and if the dose is missed or not taken at the established time, it should be retaken as soon as possible, but if it is less than 12 hours before the next scheduled dose, there is no need to make up the dose. Toxicity monitoring and dose adjustment should be directed by a physician.
Dosage of Ivosidenib(Tibsovo) for adult use
Knowing the dosage of Ivosidenib(Tibsovo) for adults is key to ensuring efficacy and reducing adverse effects.
Recommended dose
The recommended dose of Ivosidenib(Tibsovo) is 500 mg orally once daily until disease progression or unacceptable toxicity. Patients should be treated for at least 6 months to fully observe the clinical response.
Medication precautions
Ivosidenib(Tibsovo) can be taken orally on an empty stomach or after meals, but high-fat meals should be avoided to avoid increasing blood concentrations. The drug should be swallowed whole, not broken or crushed. Tibsovo should be taken at a fixed time every day, and if you miss a dose or do not take it at the scheduled time, you should make up the dose as soon as possible, but if it is less than 12 hours before the next scheduled dose, you do not need to make up the dose.
Toxicity monitoring and dose adjustment
During treatment, blood counts, blood biochemistry, and electrocardiogram (ECG) should be monitored regularly to detect and manage toxicity in a timely manner. Depending on the severity of the toxicity, it may be necessary to suspend the drug, lower the dose, or stop it permanently. The specific dose adjustment regimen depends on the doctor's recommendation.
Following the dosage and precautions for adults with Ivosidenib(Tibsovo) can help ensure efficacy and patient safety.
What drugs does Ivosidenib(Tibsovo) interact with?
Understanding the drug interactions of Ivosidenib(Tibsovo) can help avoid potential adverse effects.
Interaction with strong CYP3A4 inhibitors
Concomitant use of Ivosidenib(Tibsovo) with strong CYP3A4 inhibitors may increase systemic exposure to the drug, thereby increasing the risk of toxicity. If concomitant use is required, the dose of Ivosidenib(Tibsovo) should be reduced to 250 mg and at least 5 half-lives after the discontinuation of strong CYP3A4 inhibitor therapy, and then Ivosidenib(Tibsovo) should be restored to the recommended dose.
Interaction with antacids
Co-use with gastric acid reducers may reduce the concentration of Ivosidenib(Tibsovo) and thus reduce efficacy. Concomitant use with proton pump inhibitors, H2 receptor antagonists, and topically acting antacids should be avoided. If it cannot be avoided, Ivosidenib(Tibsovo) should be taken 4 hours before or 10 hours after administration of topically acting antacids.
Potential interactions with other medications
Ivosidenib(Tibsovo) may also interact with other drugs, such as drugs known to prolong the QTc interval and antiarrhythmics. When using Ivosidenib(Tibsovo), the patient's medication history should be informed in detail so that the doctor can assess the potential risk of drug interactions.
Understanding the drug interactions of Ivosidenib(Tibsovo) can help avoid adverse reactions and ensure drug safety.
The special population of Ivosidenib(Tibsovo)?
Identifying the use of Ivosidenib(Tibsovo) in special populations can help provide patients with more personalized treatment options.
Pregnant and lactating women
Treatment with Ivosidenib(Tibsovo) in pregnant women may cause harm to the fetus and should be avoided. It is recommended to stop breastfeeding during treatment with Ivosidenib(Tibsovo) and at least 1 month after the last dose.
Elderly patients and pediatric patients
Older patients do not need to undergo dose adjustment, but liver and kidney function should be monitored. For pediatric patients, there are no clinical studies of Ivosidenib(Tibsovo) in patients younger than 18 years of age and is not recommended.
Patients with hepatic and renal insufficiency
For patients with mild or moderate hepatic or renal impairment, there is no need to adjust the starting dose. The pharmacokinetics of patients with severe hepatic and renal impairment is unclear and should be used with caution.
As an innovative AML drug targeting IDH1 mutations, Tibsovo needs to strictly follow the doctor's instructions in terms of dosage for adults, drug interactions and medication in special populations. Understanding the details of their administration can help ensure efficacy and patient safety, providing patients with a more personalized treatment plan.
